The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I think MURF was $10 pre merger as that is the baseline for SPACS so not sure that has a lot of relevance now. Post merger into CDT is when the SP volatility began. Looking at the SH list, free float is quite low at the moment so that would be a positive as interest grows. Also a lot of warrants available at $11.50 so I see that as a near term target (or in excess of even)
SHs can think big but the Board need to show that they do as well. Start off by attending to the small details that they control like updating investment page on a regular basis and releasing the quarterly update in a timely manner rather than 10 weeks post period. Improve PR. Show support for the company by purchasing some shares in the company. Then maximise returns on CDT and see where that leads.
Deacs1970, I agree a new Business Model is warranted. Long-term investing in AIM is of the bygone days. One consideration is how to maximise this opportunity. Vela has carry forward tax losses of £5.3m which means they will be fully be utilised if CDT sale price is ~$10. At that level, I would consider selling off the losers (or the whole portfolio even) and absorb into the CDT gains. That leave the company with a big pot of cash to start again.
Interim results should be issued shortly, last year they came out on 15 Dec.
From SEC doc
We do not intend to provide additional funding to develop AZD1656 for Covid-19. However, we are entitled to a portion of the revenues in the event that AZD1656 is further developed by St. George Street or another third party and is monetized, whether through a sale, license agreement, or otherwise.
Excalibur/UKRI appear to have retained their % ownership of AZD1656 so perhaps there is some future hope/plans to monetise, just not directly thru CDT.
I think that has always been the issue here. Could do with several more TR1 holders to provide that stability. Need some form of coherent & viable strategic investment plan for that to happen one feels. Otherwise as you say, rises will be sold into to.
Yes, I understand your point to look forwards to a new beginning with a healthy bank balance. It is just whether the existing team, based on past performance have the ability to steer the company in a new and successful direction.
Yep, agree that it is about time there was an update on Aeristech and whether there is a proposed ipo or any general news even. I do not think that this or any other of the investee companies can move the needle now. It is CDT or bust!
It is too simplistic to say poor performance is solely due to AIM market conditions. Management have continually failed to adapt to the situation. They do not appear to recognize this and correct their path, but then again there are absolutely no consequences so no compelling reason to I guess.
Agree, let's start off with the quarterly update being issued on a timely basis. Then include current holdings, especially as there has been quite a few sales recently. Then get rid of companies they met section, totally useless info if they do not provide any context (and take no action).